




PHARMACEUTICAL 2023

Zoetis Inc.
Rank 229 of 446





RealRate

PHARMACEUTICAL 2023

Zoetis Inc.
Rank 229 of 446



The relative strengths and weaknesses of Zoetis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Zoetis Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 76%, being 33% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,506,000
Cost of Goods Sold	2,454,000
Intangible Assets	4,126,000
Liabilities, Current	3,167,000
Liabilities, Non-Current	6,955,000
Other Assets	540,000
Other Compr. Net Income	-50,000
Other Expenses	927,000
Other Liabilities	400,000
Other Net Income	-40,000
Other Revenues	8,080,000
Property and Equipment	2,753,000
Research and Development	539,000
Selling, General and Administrative Expense	2,009,000

Output Variable	Value in 1000 USD
Assets	14,925,000
Liabilities	10,522,000
Expenses	5,929,000
Revenues	8,080,000
Stockholders Equity	4,403,000
Net Income	2,111,000
Comprehensive Net Income	2,086,000
Economic Capital Ratio	76%